



## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(88) Valproic acid</b>	[mg/L]				12							12	11	92%							0		
Samples and groups																							
<b>Sample A1</b>		34,7	5,1	15	12	CVP	35,3	0,84	20%	28,2	42,4	12	11	92%							0		
(6) Immunoturbidimetry, KIMS		34,2	2,8	8,2	5	0						5											
Other					7	0						7											
							1x 1, 2x 2, 4x 4																
<b>Sample B1</b>		126	13	10	12	CVP	127	2,1	20%	101	153	12	12	100%							0		
(6) Immunoturbidimetry, KIMS		121	9,1	7,5	5	0						5											
Other					7	0						7											
							1x 1, 2x 2, 4x 4																
<b>(82) Theophylline</b>	[mg/L]				4																4	4	100%
Samples and groups																							
<b>Sample A1</b>		20,8	3,5	17	4									CRV	22,58	0,23	24%	17,1	28	4	4	100%	
Other					4	0															4		
							1x 2, 2x 4, 1x 6																
<b>Sample B1</b>		17,2	2,6	15	4									CRV	18,39	0,18	24%	13,9	22,9	4	4	100%	
Other					4	0															4		
							1x 2, 2x 4, 1x 6																
<b>Set 2</b>																							
<b>(89) Amicacin</b>	[mg/L]				4							4	3	75%							0		
Samples and groups																							
<b>Sample A2</b>		18,7	3,0	16	4	CVP	18,1	0,35	20%	14,4	21,8	4	4	100%							0		
Other					4	0						4											
							3x 2, 1x 6																
<b>Sample B2</b>		30,8	8,0	26	4	CVP	29,8	0,54	20%	23,8	35,8	4	3	75%							0		
Other					4	0						4											
							3x 2, 1x 6																
<b>(90) Gentamicin</b>	[mg/L]				12							12	12	100%							0		
Samples and groups																							
<b>Sample A2</b>		7,46	1,5	20	12							12	12	100%							0		
Other					12	0						12											
							1x 0, 1x 1, 3x 2, 4x 4, 2x 6, 1x 6/60																
<b>Sample B2</b>		3,61	0,58	16	12							12	12	100%							0		
Other					12	0						12											
							1x 0, 1x 1, 3x 2, 4x 4, 2x 6, 1x 6/60																
<b>(93) Methotrexate</b>	[µmol/L]				3							3	3	100%							0		
Samples and groups																							
<b>Sample A2</b>		3,16	0,35	11	3	CVP	3,21	0,25	30%	2,24	4,18	3	3	100%							0		
Other					3	0						3											
							1x 2, 2x 4																
<b>Sample B2</b>		1,08	0,03	3,1	3	CVP	1,1	0,052	30%	0,77	1,43	3	3	100%							0		
Other					3	0						3											
							1x 2, 2x 4																
<b>(92) Vankomycin</b>	[mg/L]				13							13	13	100%							0		
Samples and groups																							
<b>Sample A2</b>		11,2	0,74	6,6	13	CVP	11	0,24	28%	7,92	14,1	13	13	100%							0		
(4) LIA, ILMA		11,7	0,53	4,5	6	0						6											

